Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...
Streetwise Reports | November 19, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. In an Aug. 20 research note, analyst Ed Arce reported that H.C. Wainwright & Co. raised its target price on Nabriva Therapeutics Plc (NBRV:NASDAQ) to $8 per sh...
Streetwise Reports | August 28, 2019 |

Mexican gold junior I really like

Editor’s note: The Pediment Gold story was first reported by Ticker Trax’s Thom Calandra in an article posted her e . I first wrote about Pediment Gold Corp ( TSX: T.PEZ , Stock Forum ) in a private report delivered on June 18, 2007....
Michael S. (Mickey) Fulp | October 28, 2012 |

The Dales Report panelists agree on this vote: Way to go, Ohio

Welcome to the Trade To Black podcast on Stockhouse.com . In the episode in the above video, Shadd Dales, Anthony Varrell and Benjamin Smith talk in-depth about the following stories and more: Ohio voters approve the legalization of adult use cannabis ...
The Dales Report | November 9, 2023 |

This Signal Points To More Upside In Stocks

NEW MONTHLY SIGNALS The MSCI World Index tracks over one thousand large and mid-cap stocks in twenty-two developed countries, covering 85% of the market capitalization in those regions. As shown via the chart below, a positive monthly MACD cross was just nailed down on the...
Chris Ciovacco | December 3, 2019 |

Precious Metals Hit Resistance

The precious metals sector may have begun a correction on Wednesday. The miners (GDX, GDXJ) sold off after reaching significant resistance levels while the metals are trading just below significant resistance levels. We mentioned these targets in our article last wee...
Jordan Roy-Byrne, CMT | May 22, 2020 |

Growing Rapidly and Efficiently in California's Cannabis Market

This podcast is part of our Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public marketplace. Stockhouse Media's Omri Wallach was recently joined live by Arni ...
Omri Wallach | September 30, 2019 |

PODCAST: How this Cannabis Co. is Creating a Self-Contained Ecosystem

This podcast is part of our Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public marketplace. Stockhouse Media's Dave Jackson was recently joined live by Arni ...
Dave Jackson | August 21, 2019 |

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. This...
Streetwise Reports | January 9, 2020 |
1 2 3 4 5 6 7 8 9 10